Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

CureVac (Group)

CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is advancing the field of mRNA-based vaccination. The company uses its technology platforms for the development of novel therapeutic mRNA vaccines (RNActive®) for cancer and prophylactic vaccines for infectious diseases. Furthermore CureVac develops adjuvants based on non-coding RNAs (RNAdjuvant®) for enhancing the immune response of other vaccines. The company has successfully completed Phase I/IIa studies with its RNActive® cancer vaccines in prostate cancer and non-small cell lung cancer (NSCLC). Results so far have shown that mRNA-based products are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses. CureVac is currently running a number of clinical trials with its RNActive® vaccines, including a large randomized Phase IIb clinical trial in prostate cancer. In addition to developing its own pipeline, CureVac is collaborating with Sanofi Pasteur,In-Cell-Art and Janssen Pharmaceuticals for the development of prophylactic vaccines in infectious diseases utilizing its RNActive® technology platform. *

 

Period Start 2000-08-01 established
  Predecessor University of Tübingen (Eberhard-Karls-Universität)
Products Industry RNAi technology
  Industry 2 RNActive® vaccination technology
Person Person Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
     
Region Region Tübingen
  Country Germany
  Street 15 Paul-Ehrlich-Str.
  City 72076 Tübingen
  Tel +49-7071-92053-0
    Address record changed: 2017-10-29
     
Basic data Employees D: 101 to 500 (2017-10-26)
     
    * Document for �About Section�: CureVac GmbH. (11/4/13). "Press Release: CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enalbe Clinical Testing of Novel Immunotherapy Treatment Options for Cancer". Tübingen & New York, NY.
     
   
Record changed: 2018-12-07

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top